Programmed cell death protein 1 on natural killer cells: fact or fiction?

Programmed cell death protein 1 (PD-1) has become one of the most investigated targets for cancer immunotherapy. Most research has centered on inhibiting PD-1 on T cells, but there is increased interest in understanding the role of PD-1 on NK cells. While the expression of PD-1 on NK cells has been...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 2020-06, Vol.130 (6), p.2816-2819
Main Authors: Cho, Monica M, Quamine, Aicha E, Olsen, Mallery R, Capitini, Christian M
Format: Article
Language:English
Subjects:
Animals
Apoptosis
B7-H1 Antigen
Biochemistry
Cancer research
Cancer treatment
Dogs
Humans
Immunotherapy
Killer cells
Killer Cells, Natural
Mice
Nivolumab
Pembrolizumab
Programmed Cell Death 1 Receptor - genetics
T cells
T-Lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c579t-24699c18cdc61fa51e9f2873f63f88c8918533242d7e975604b68a9b9a340a973
cites cdi_FETCH-LOGICAL-c579t-24699c18cdc61fa51e9f2873f63f88c8918533242d7e975604b68a9b9a340a973
container_end_page 2819
container_issue 6
container_start_page 2816
container_title The Journal of clinical investigation
container_volume 130
creator Cho, Monica M
Quamine, Aicha E
Olsen, Mallery R
Capitini, Christian M
description Programmed cell death protein 1 (PD-1) has become one of the most investigated targets for cancer immunotherapy. Most research has centered on inhibiting PD-1 on T cells, but there is increased interest in understanding the role of PD-1 on NK cells. While the expression of PD-1 on NK cells has been controversial, with papers publishing contradictory results in multiple models, there is increased clinical interest in NK and PD-1 immunotherapy. In this issue of the JCI, Judge et al. comprehensively explore the lack of PD-1 expression on murine, canine, and human NK cells and the clinical implication of these findings.
doi_str_mv 10.1172/JCI137051
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7260016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A627278050</galeid><sourcerecordid>A627278050</sourcerecordid><originalsourceid>FETCH-LOGICAL-c579t-24699c18cdc61fa51e9f2873f63f88c8918533242d7e975604b68a9b9a340a973</originalsourceid><addsrcrecordid>eNqNksuKFDEUhoMoTju68AUkIIguasylqpK4UIZGxx4GRrxtQzqVVEerkjZJib69qbk009ALySKQfOc_tx-ApxidYMzI6_PlClOGGnwPLHDT8IoTyu-DBUIEV4JRfgQepfQDIVzXTf0QHFFCBeaIL8DqUwx9VONoOqjNMMDOqLyB2xiycR5iGDz0Kk9RDfCnGwYTr7D0BlqlMwwRWqezC_7dY_DAqiGZJzf3Mfj24f3X5cfq4vJstTy9qHTDRK5I3QqhMdedbrFVDTbCEs6obanlXPNSV0MpqUnHjGBNi-p1y5VYC0VrpEozx-Dtte52WpeqtfG5FCe30Y0q_pVBObn_491G9uG3ZKQtE2iLwMsbgRh-TSZlObo0N6W8CVOSpEYYCdRiVNDn12ivBiOdt6Eo6hmXpy1hhHHUzFR1gOqNNyV98Ma68rzHnxzgy-nM6PTBgFd7AYXJ5k_u1ZSSXH35_P_s5fd99sUddmPUkDcpDNO8z3RQVMeQUjR2N26M5GxBubNgYZ_d3c-OvPUc_QfkVNBO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2401090610</pqid></control><display><type>article</type><title>Programmed cell death protein 1 on natural killer cells: fact or fiction?</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Cho, Monica M ; Quamine, Aicha E ; Olsen, Mallery R ; Capitini, Christian M</creator><creatorcontrib>Cho, Monica M ; Quamine, Aicha E ; Olsen, Mallery R ; Capitini, Christian M</creatorcontrib><description>Programmed cell death protein 1 (PD-1) has become one of the most investigated targets for cancer immunotherapy. Most research has centered on inhibiting PD-1 on T cells, but there is increased interest in understanding the role of PD-1 on NK cells. While the expression of PD-1 on NK cells has been controversial, with papers publishing contradictory results in multiple models, there is increased clinical interest in NK and PD-1 immunotherapy. In this issue of the JCI, Judge et al. comprehensively explore the lack of PD-1 expression on murine, canine, and human NK cells and the clinical implication of these findings.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/JCI137051</identifier><identifier>PMID: 32391808</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Animals ; Apoptosis ; B7-H1 Antigen ; Biochemistry ; Cancer research ; Cancer treatment ; Dogs ; Humans ; Immunotherapy ; Killer cells ; Killer Cells, Natural ; Mice ; Nivolumab ; Pembrolizumab ; Programmed Cell Death 1 Receptor - genetics ; T cells ; T-Lymphocytes</subject><ispartof>The Journal of clinical investigation, 2020-06, Vol.130 (6), p.2816-2819</ispartof><rights>COPYRIGHT 2020 American Society for Clinical Investigation</rights><rights>2020 American Society for Clinical Investigation 2020 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c579t-24699c18cdc61fa51e9f2873f63f88c8918533242d7e975604b68a9b9a340a973</citedby><cites>FETCH-LOGICAL-c579t-24699c18cdc61fa51e9f2873f63f88c8918533242d7e975604b68a9b9a340a973</cites><orcidid>0000-0002-6708-9578 ; 0000-0002-9049-7078</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260016/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260016/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32391808$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cho, Monica M</creatorcontrib><creatorcontrib>Quamine, Aicha E</creatorcontrib><creatorcontrib>Olsen, Mallery R</creatorcontrib><creatorcontrib>Capitini, Christian M</creatorcontrib><title>Programmed cell death protein 1 on natural killer cells: fact or fiction?</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Programmed cell death protein 1 (PD-1) has become one of the most investigated targets for cancer immunotherapy. Most research has centered on inhibiting PD-1 on T cells, but there is increased interest in understanding the role of PD-1 on NK cells. While the expression of PD-1 on NK cells has been controversial, with papers publishing contradictory results in multiple models, there is increased clinical interest in NK and PD-1 immunotherapy. In this issue of the JCI, Judge et al. comprehensively explore the lack of PD-1 expression on murine, canine, and human NK cells and the clinical implication of these findings.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>B7-H1 Antigen</subject><subject>Biochemistry</subject><subject>Cancer research</subject><subject>Cancer treatment</subject><subject>Dogs</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Killer cells</subject><subject>Killer Cells, Natural</subject><subject>Mice</subject><subject>Nivolumab</subject><subject>Pembrolizumab</subject><subject>Programmed Cell Death 1 Receptor - genetics</subject><subject>T cells</subject><subject>T-Lymphocytes</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNksuKFDEUhoMoTju68AUkIIguasylqpK4UIZGxx4GRrxtQzqVVEerkjZJib69qbk009ALySKQfOc_tx-ApxidYMzI6_PlClOGGnwPLHDT8IoTyu-DBUIEV4JRfgQepfQDIVzXTf0QHFFCBeaIL8DqUwx9VONoOqjNMMDOqLyB2xiycR5iGDz0Kk9RDfCnGwYTr7D0BlqlMwwRWqezC_7dY_DAqiGZJzf3Mfj24f3X5cfq4vJstTy9qHTDRK5I3QqhMdedbrFVDTbCEs6obanlXPNSV0MpqUnHjGBNi-p1y5VYC0VrpEozx-Dtte52WpeqtfG5FCe30Y0q_pVBObn_491G9uG3ZKQtE2iLwMsbgRh-TSZlObo0N6W8CVOSpEYYCdRiVNDn12ivBiOdt6Eo6hmXpy1hhHHUzFR1gOqNNyV98Ma68rzHnxzgy-nM6PTBgFd7AYXJ5k_u1ZSSXH35_P_s5fd99sUddmPUkDcpDNO8z3RQVMeQUjR2N26M5GxBubNgYZ_d3c-OvPUc_QfkVNBO</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Cho, Monica M</creator><creator>Quamine, Aicha E</creator><creator>Olsen, Mallery R</creator><creator>Capitini, Christian M</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6708-9578</orcidid><orcidid>https://orcid.org/0000-0002-9049-7078</orcidid></search><sort><creationdate>20200601</creationdate><title>Programmed cell death protein 1 on natural killer cells: fact or fiction?</title><author>Cho, Monica M ; Quamine, Aicha E ; Olsen, Mallery R ; Capitini, Christian M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c579t-24699c18cdc61fa51e9f2873f63f88c8918533242d7e975604b68a9b9a340a973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>B7-H1 Antigen</topic><topic>Biochemistry</topic><topic>Cancer research</topic><topic>Cancer treatment</topic><topic>Dogs</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Killer cells</topic><topic>Killer Cells, Natural</topic><topic>Mice</topic><topic>Nivolumab</topic><topic>Pembrolizumab</topic><topic>Programmed Cell Death 1 Receptor - genetics</topic><topic>T cells</topic><topic>T-Lymphocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cho, Monica M</creatorcontrib><creatorcontrib>Quamine, Aicha E</creatorcontrib><creatorcontrib>Olsen, Mallery R</creatorcontrib><creatorcontrib>Capitini, Christian M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale_Opposing Viewpoints In Context</collection><collection>Gale In Context: Science</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cho, Monica M</au><au>Quamine, Aicha E</au><au>Olsen, Mallery R</au><au>Capitini, Christian M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Programmed cell death protein 1 on natural killer cells: fact or fiction?</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>130</volume><issue>6</issue><spage>2816</spage><epage>2819</epage><pages>2816-2819</pages><issn>0021-9738</issn><eissn>1558-8238</eissn><abstract>Programmed cell death protein 1 (PD-1) has become one of the most investigated targets for cancer immunotherapy. Most research has centered on inhibiting PD-1 on T cells, but there is increased interest in understanding the role of PD-1 on NK cells. While the expression of PD-1 on NK cells has been controversial, with papers publishing contradictory results in multiple models, there is increased clinical interest in NK and PD-1 immunotherapy. In this issue of the JCI, Judge et al. comprehensively explore the lack of PD-1 expression on murine, canine, and human NK cells and the clinical implication of these findings.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>32391808</pmid><doi>10.1172/JCI137051</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-6708-9578</orcidid><orcidid>https://orcid.org/0000-0002-9049-7078</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 2020-06, Vol.130 (6), p.2816-2819
issn 0021-9738
1558-8238
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7260016
source PubMed Central; EZB Electronic Journals Library
subjects Animals
Apoptosis
B7-H1 Antigen
Biochemistry
Cancer research
Cancer treatment
Dogs
Humans
Immunotherapy
Killer cells
Killer Cells, Natural
Mice
Nivolumab
Pembrolizumab
Programmed Cell Death 1 Receptor - genetics
T cells
T-Lymphocytes
title Programmed cell death protein 1 on natural killer cells: fact or fiction?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A41%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Programmed%20cell%20death%20protein%201%20on%20natural%20killer%20cells:%20fact%20or%20fiction?&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Cho,%20Monica%20M&rft.date=2020-06-01&rft.volume=130&rft.issue=6&rft.spage=2816&rft.epage=2819&rft.pages=2816-2819&rft.issn=0021-9738&rft.eissn=1558-8238&rft_id=info:doi/10.1172/JCI137051&rft_dat=%3Cgale_pubme%3EA627278050%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c579t-24699c18cdc61fa51e9f2873f63f88c8918533242d7e975604b68a9b9a340a973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2401090610&rft_id=info:pmid/32391808&rft_galeid=A627278050&rfr_iscdi=true